Engineering Therapeutic Microbubbles

Lead Research Organisation: University of Leeds
Department Name: Physics and Astronomy

Abstract

Colorectal Cancer (CRC) is the third most common cancer in the UK, with approximately 32,300 new cases diagnosed and 14,000 deaths in England and Wales each year. Occurrence of colorectal cancer is strongly related to age, with 83% of cases arising in people older than 60 years. It is anticipated that as our elderly population increases, CRC will increase in prevalence (National Institute for Clinical Excellence, www.nice.org.uk). This raises important questions relating to treatment in elderly patients balanced with quality-of-life and health economics considerations. The challenge to nanotechnology and engineering is to deliver cost-effective, less invasive treatments with fewer side-effects and potential benefits for quality of life in patients. This is particularly important in CRC at the present time as the NHS bowel-screening programme is rolled out for all individuals aged 60 to 69. This raises important issues for rapid, accurate, and acceptable, safe and cost-effective investigation and treatment of older symptomatic patients. Ultrasound has a clear and growing role in modern medicine and there is increasing demand for the introduction of ultrasound contrast agents such as microbubbles (MBs). These MBs are typically less than one hundredth of a millimetre in size, so that they can pass through the vasculature, and lead to imaging enhancements by scattering of the ultrasound signal. So-called third generation MBs will not only perform functional imaging with greatly enhanced sensitivity and specificity but will also carry therapeutic payloads for treatment or gene therapy. These will most likely be released by destroying the bubbles at the targeted site and their effect enhanced further by sonoporation (sound induced rupture of the cell walls to allow drugs in). Although the focus of our proposal is therapeutic delivery for cancer treatment, the basic technologies for MB development and ultrasound technology are equally applicable to other conditions e.g. cardiovascular and musculoskeletal disease where there is an unmet clinical need, particularly in ageing populations. As such this is a generic technology development relevant to different diseases.Our programme of research addresses several key issues central for the successful development of these 3rd Generation MBs. Firstly, we propose to develop a machine, based on microfluidics, for the creation of MBs of uniform size (necessary for human application). This instrument will also allow us to put suitable coatings on the MBs to target them specifically at cancerous cells. Secondly, we will develop novel coatings to allow control over the way bubbles respond to ultrasound signals. We will then add payloads of the required drug to be delivered onto the micro-bubble surface. At the same time we will develop novel methods of generating ultrasound signals which can be used to selectively destroy the MBs and simultaneously create holes in the cells to which the drugs should be delivered. A necessary part of such a programme of research is the full testing and evaluation of the MBs developed for targeted therapy of CRC using a combination models. Firstly, against cancer cells grown in test tubes and secondly, against mice infected with the relevant cancer. At the conclusion of our research project we will have enhanced our understanding of how MB and ultrasound technologies can be combined to yield new routes for therapeutic delivery/gene therapy. This will provide a platform to launch the next stage of research, required before such an approach could be used clinically.

Planned Impact

The research proposed here would have a combination of short- and long-term beneficiaries. Most directly, and immediately, affected will be those engaged in translational research, especially that involving the training of new PDRAs and PhDs, within the University of Leeds. For these it will serve to reinforce the benefits of following a multidisciplinary approach to targeting specific medical problems. This project will broaden the base of researchers engaged in therapeutic delivery through a combination of open internal meetings, such as the journal club, and a project seminar programme. Outside the University of Leeds there are other beneficiaries, both academic and industrial who will be users of the research outputs in the medium-term. For example, researchers engaged in the development of ultrasound contrast agents and also those wishing to establish new delivery modes will benefit from having an instrument for the facile and low-cost production of microbubbles (MBs) with improved control over MB size and surface coating. Access to both the microfluidic chips and microbubble instrumentation will be ensured through our commercialisation of this product. In this respect local commerce (private sector) will also be a beneficiary of this research. In the medium-term we will deliver improved understanding in the relationship between the MB coating and ultrasound (US) response and improved mechanisms for US controlled drug release, which will help a number of researchers, develop improved protocols for therapeutic delivery and/or enhance preclinical investigations. Dissemination of our research outputs will be achieved through our organisation of an annual symposium, through publication in high impact journals and via presentations at relevant international meetings. In the longer term this research will lead to new, more effective modes of therapeutic delivery thereby allowing reduced systemic exposure to potent drugs and concomitantly reduced cost and hence will therefore be of interest to big pharma and charitable organisations engaged with improving the treatment of disease. At this early stage we have made contact with a number of large charitable organisations and relevant pharmaceutical companies (from whom we have letters of support) and will keep these companies informed of our progress during the project as well as welcoming them to our annual meetings. The ultimate beneficiaries would be clinicians involved in the deliver of, and the general public as primary recipients of, the technology to be developed. These would benefit from improved efficacy of treatment with reduced side effects and overall improvement in the quality of life, and life expectancy. Finally, the reduced drug content and associated severity of side effects should lead to a reduction in the overall cost of treatment, and, thus could benefit taxpayers.

Publications

10 25 50
 
Description The Key Scientific Outcomes are; i) Development of a new mF 'spray-regime' capable of producing MBs of clinically relevant sizes and concentration (GB1111082.2).1 ii) Demonstration of methods for the on-chip manipulation of MBs using electric fields (GB1111081.4). iii) Production of three prototype instruments with excellent reproducibility across multiple users / locations capable of producing monodisperse MBs.1 iv) Demonstration of the addition of therapeutic payloads, Irinotecan, Doxorubicin, as well as fluorophores (Luciferin, Qdots and dyes) in the form of antibody labelled pegylated-liposomes. v) Improved in vivo MB lifetimes, over commercially available imaging-MBs. vi) The first determination of the mechanical properties of lipid-shelled bubbles at clinically relevant temperatures using AFM.2 vii) The programming of arbitrary ultrasonic sequences onto a medical phased array transducer3,4 (GB1222882.1) using the University of Leeds (UoL) built Ultrasound Array Research Platform (UARP). viii) Development of the acoustic trap for increasing local MB concentration (GB1205158.7)5, ix) Development of a sonoporation test-bed, where the efficacy of acoustic pulse regimes were explored for CRC cell lines and tumours in nude mice.6 x) Demonstration that mF MBs are stable and non-toxic, can be targeted, and bind to endothelial cells6 and tumour cells6 under flow conditions in vitro and in vivo. xi) Improved uptake in human CRC xenografts of luciferin as a model drug when targeted to tumour vasculature via anti-VEGFR2 antibody. xii) Improved in vitro uptake of a model drug using MBs combined with CHIRP sequences.7 xiii) Demonstration that high-frequency US can be used to simultaneously image tumour growth/development and provide quantitative perfusion data in vivo in mouse models of CRC, xiv) Demonstration that high frequency ultrasound can be used to image and measure colon wall thickness in vivo over time8 and image adenomas in the mouse colon9. This extends the range of mouse models suitable for translational studies of targeted, US triggered therapeutic MBs.
Exploitation Route As part of this project we are developing a platform for preclinical, in vitro and in vivo investigations, of sono-enhanced drug delivery. We expect this to be of use to a wide range of SME and larger pharmaceutical companies.



In the longer term we expect therapeutic delivery to be taken into the the clinic providing a more efficient route for therapeutic delivery with improved patient outcome and reduced side effects. Outside the University of Leeds there are other beneficiaries, both academic and industrial who will be "users" of the research outputs in the medium-term. For example, Epigem Ltd, a long-standing partner in our research, will exploit the commercial development of the instrumentation to provide microfluidic system for sale to researchers and companies engaged in CEUS imaging and therapeutic delivery. The research undertaken in this project has led to the development of a new instrument the "Horizon" a microfluidics based microbubble instrument developed (http://epigem.co.uk/latest-news/epigem-and-university-of-leeds-unveil-first-microbubble-instrument-the-horizon) for the on demand production of targeted micro bubbles. Researchers engaged in targeted imaging and therapeutic delivery will now have access to simple low cost routes for on demand production of monodisperse and spray regime produced MBs. Importantly they will be able to specify in vivo lifetimes and microbubble rigidity (US response). This will allow optimisation of targeting and delivery regimens. Access to the microfluidic chips developed will be ensured through our continued links with Epigem. University of Leeds and Epigem are commercialising this instrument.





In the longer term this research will lead to new, more effective modes of therapeutic delivery thereby allowing reduced systemic exposure to potent drugs and concomitantly reduced cost and hence will therefore be of interest to big pharma and charitable organisations engaged with improving the treatment of disease. At this early stage we have maintained our contact with a number of large charitable organisations and relevant pharmaceutical companies (from whom we have letters of support) and will keep these companies informed of our progress during the project as well as welcoming them to our annual meetings.
Sectors Healthcare

URL http://microbubbles.leeds.ac.uk/
 
Description Microfluidics aspect is being commercialised to set-up a spinout for the production of instruments for microbubble and droplet formation. We are currently in discussion with the Medicines Discovery catapult on how to move the commercialisation forward. As part of this we are attending the North of England accelerator boot camp event to aid commercialisation. Within Leeds we have refined and defended key patents held around the Horizon instrument. research has led to follow-on funding for the treatment of cancer and has widened the number of researchers in the field. The research symposia associated with this grant led to the world leaders from USA and Holland, Japan, Spain, France and Germany to come to Leeds. A number of companies attending this meeting have made sales through associated meeting. Further we have made sales of a prototype instrument for the generation of therapeutic micro bubbles to world leading medical centres in the USA and Netherlands. New clinical ultrasound /microbubble areas emerging
First Year Of Impact 2020
Sector Education,Healthcare
Impact Types Economic

 
Description International Agency for Research on Cancer (World Health Organisation)
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact UK - nominated Scientific Advisory board member 2008-2012 .
 
Description Microbubbles for hydrophobic drug delivery and enhanced diagnostics; towards personalised healthcare for the treatment of colorectal cancer
Amount £689,430 (GBP)
Funding ID EP/K023845/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2013 
End 09/2016
 
Description Conducting Polymer for Cancer Therapy 
Organisation Wellcome Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution in Wellcome Trust Institutional Strategic Support Fund (ISSF) Junior Investigator Development Fellowship
Start Year 2012
 
Description Laboratory Visit - Nidderdale High School 
Organisation Nidderdale High School
Country United Kingdom 
Sector Private 
PI Contribution October 2012 Widening participation and research engagment
Start Year 2012
 
Description Nanobombs for breast cancer diagnosis and therapy 
Organisation The Leverhulme Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Early Career Fellowship from The Leverhulme Trust, reference ECF-2013-247. 36 months.
Start Year 2013
 
Title BUBBLE GENERATION 
Description This invention relates to bubble generation, in particular to microbubble generation in a microfluidic device, which bubbles may be useful as contrasting agents or drug delivery vehicles. The invention further relates to apparatuses, systemsand methods for manufacturing said microbubbles, microbubbles produced by such methods and to their uses, e.g. in medical, diagnostic and other such applications. The microbubbles are preferentially formed using a microspray regime. 
IP Reference WO2013001309 
Protection Patent application published
Year Protection Granted 2013
Licensed No
Impact Discovery of ability to create nano bubbles - in novel way.
 
Title ULTRASOUND GENERATION 
Description An ultrasound generator comprising a signal generator and a transducer, and a method of generating ultrasound. The signal generator is arranged to receive, generate or calculate when instructed a modulating signal with a magnitude that varies within a first range, the signal generator is further arranged to generate a pulsed drive signal having a predefined first relationship to the modulating signal, the pulsed drive signal having at least a zero output level, a positive output level and a negative output level, wherein the position and width of pulses are defined by at least first and second switching angles per half cycle of the modulating signal. The transducer is arranged to generate ultrasound in response to the pulsed drive signal. The first relationship is selected such that within at least part of the range of magnitude of the modulating signal the first and second switching angles are adjusted simultaneously to provide for an increase or decrease in the magnitude of the fundamental frequency of the pulsed drive signal corresponding to an increase or decrease in the magnitude of the modulating signal. The first relationship is also selected such that a selected harmonic component of the generated pulsed drive signal is maintained below a first threshold. 
IP Reference WO2014096789 
Protection Patent application published
Year Protection Granted 2014
Licensed No
Impact N/A
 
Description Academy of Medical Sciences 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Clinical Academic Careers Committee Member

2008-2011 .
Year(s) Of Engagement Activity 2008,2009,2010,2011
 
Description Arthritis Research UK 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Chairman Scientific Strategy Committee and Trustee

2009 to present .
Year(s) Of Engagement Activity 2009,2010,2011,2012,2013,2014,2015,2016
 
Description BBSRC: The Genome Analysis Centre 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Institute Board Chairman, 2010 - 2012 .
Year(s) Of Engagement Activity 2010,2011,2012
 
Description Berlin Institue of Health 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact German Federal Ministry of Education and Research (BMBF), Scientific Review Panel Member - 2013 ro present .
Year(s) Of Engagement Activity 2013,2014,2015,2016
 
Description Charles Rodolphe Brupbacher Stifung 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Zurich, Scientific Advisory board to the Foundation member, 2012 to present .
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
 
Description Counter flow microbubble channelling using acoustic radiation force funnel 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Leeds Oncological Engineering Conference, University of Leeds 2011



Prize winning poster.
Year(s) Of Engagement Activity 2011
 
Description Daniel Turnberg Trust Panel Member 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Academy of Medical Sciences

2008 to present .
Year(s) Of Engagement Activity 2008,2010,2011,2012,2013,2014,2015,2016
 
Description Department of Health 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact NIHR/MHRA, Chairman, Clinical Practice Research Datalink, Expert Advisory group, 2012 to present .
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
 
Description Department of Health, Senior Responsible Owner and Board Chairman 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact NIHR/NHS Connecting for Health, Research Capability Programme, 2007-2012 .
Year(s) Of Engagement Activity 2007,2008,2009,2010,2011,2012
 
Description Deutsche Krebshilfe Programme for the development of interdisciplinary Oncology Centres of excellence in Germany 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Clinical Advisory Board Member

2008 to present .
Year(s) Of Engagement Activity 2008,2009,2010,2011,2012,2013,2014,2015,2016
 
Description Facebook Interview 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact · Our Facebook promotion reached 195,949 people, with a total of 207,498 impressions and 16,300 "results" - which is people engaging with the post in some way (click throughs, likes, shares, video views etc)

· Over 10,000 views of the Facebook live interview with Steve and Sally, and many great comments saying people will donate. The video reached over 36,000 people
Year(s) Of Engagement Activity 2018
 
Description German Consortium for Translational Cancer Research of the Federal Ministry of Education and Research (DKTK) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Review panel chairman - 2010 to present

Scientific Advisory Board member - 2013 to present .
Year(s) Of Engagement Activity 2010,2011,2012,2013,2014,2015,2016
 
Description German Helmholtz Association (DKFZ, MDC, HZDR) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Cancer Research Programme, Internation Review Panel member

2013 to present .
Year(s) Of Engagement Activity 2013,2014,2015,2016
 
Description Imaging the tumour microenvironment with contrast enhanced high frequency ultrasound 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Sheffield, Cancer Research Centre 2013

Invited presentation.
Year(s) Of Engagement Activity 2013
 
Description International Agency for Research on Cancer (IARC/WHO) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact UK-nominated Fellowships Committee Member - 2012 to present .
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
 
Description International Network for Cancer Treatment and Research 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact INCTR/WHO, building capacity for cancer control in developing countries



Governing Council Member , 2011 to present .
Year(s) Of Engagement Activity 2011,2012,2013,2014,2015,2016
 
Description Invited Seminar Sheffield University 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Dr Peyman gave an invited seminar talk at the School of Physics, Sheffield University
Year(s) Of Engagement Activity 2018
 
Description Invited Seminar talk - Heriot-Watt University, Edinburgh 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Dr Peyman was invited to give a talk on her research at Leeds at Heriot-Watt University in which she included work on therapeutic microbubbles
Year(s) Of Engagement Activity 2018
 
Description Lab Visit - Sounding out Bubbles 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact A novel approach to treating cancer

Lab visit and presentation

Myeloma Support group, October 2012.
Year(s) Of Engagement Activity 2012
 
Description Leeds microbubble symposium: fabrication, characterisation and translational applications (Leeds 2012) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact 'High on-chip production rates and mechanical characterisation of therapeutic microbubbles for targeted drug delivery' - oral presentation.
Year(s) Of Engagement Activity 2012
 
Description Li Ka Shing Institute of Health Sciences at the Chinese University of Hong Kong 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Steering Committee Member, 2007-2010 .
Year(s) Of Engagement Activity 2007,2008,2009,2010
 
Description MRC Centre for Drug Safety Science 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact University of Liverpool

Scientific Advisory Board member - 2009 to present .
Year(s) Of Engagement Activity 2009,2010,2011,2012,2013,2014,2015,2016
 
Description Matrix metalloproteinase-9, Neutrophil Gelatinase-Associated Lipocalin and tumour endothelial markers in Perihilar Cholangiocarcinoma: Developing biomarkers for targeted therapies 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Association of Surgeons of Great Britain and Ireland (ASGBI) International Surgical Congress, Glasgow May 2013

Invited presentation.
Year(s) Of Engagement Activity 2013
 
Description NIHR Clinical Research Facilities for Experimental Medicine 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Funding panel - Chairman 2011 to present .
Year(s) Of Engagement Activity 2011,2012,2013,2014,2015,2016
 
Description NIHR Research Capability Programme 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Senior Responsible Owner .
Year(s) Of Engagement Activity 2014,2015
 
Description NIHR Senior Investigtors Appointment Panel 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 2007 to 2010 - Member

2011 to 2014 - Chairman .
Year(s) Of Engagement Activity 2007,2008,2009,2010,2011,2012,2013,2014
 
Description Nanomechanical properties of therapeutic microbubbles 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Oral session

UK scanning probe microscope conference.
Year(s) Of Engagement Activity 2013
 
Description National Cancer Intelligence Network 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Steering Group Chairman

2006 to present .
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016
 
Description OSCHR/NOCRI Therapeutic Capability Clusters Delivery and Oversight Group member 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 2009-2012 .
Year(s) Of Engagement Activity 2009,2010,2011,2012
 
Description Optimisation of microbubble and ultrasound technologies for the diagnostic and therapy of colorectal cancer 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Talk at IMSAT.

Invited talk In Dundee
Year(s) Of Engagement Activity 2011
 
Description Oxford University Vaccines Oversight Committee Chairman 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 2012 to present .
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
 
Description Physics Taster session talk 2018 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Dr Peyman gave a talk on bubbles for fighting cancer as part of a physics taster day for school students currently choosing University places.
Year(s) Of Engagement Activity 2018
 
Description Pint of Science public talk: Bottoms up to Bubbles: The little big bangs destroying cancer 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Dr Peyman was asked to give a talk on the bubble research as part of the nationwide Pint of Science series of talks
Year(s) Of Engagement Activity 2018
 
Description Probing the effect of Poly(ethylene glycol) on the mechanical behaviour of Streptavidin and quantum dot coated microbubbles 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact UK Scanning probe microscope conference (Edinburgh, UK, 2011).
Year(s) Of Engagement Activity 2011
 
Description Public talk - Science on the microscale: bubble bombs for fighting cancer 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Dr Peyman was invited to give a talk to the Huddersfield Women's Institute on the bubble research at Leeds
Year(s) Of Engagement Activity 2016
 
Description Public talk - Therapeutic Microbubbles 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Dr Peyman was invited to give a talk as part of a an afternoon tea raising money for Yorkshire Cancer Research.
Year(s) Of Engagement Activity 2017
 
Description Radio interview - Women's Day 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Radio interview on BBC 106.6 fm for as part of 'women's day' that featured women from a variety of professions talking about their work



Bradford Community Broadcasting, Bradford, UK.
Year(s) Of Engagement Activity 2013
 
Description Senior Medical Advisor 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Cancer Research UK

2007 to present .
Year(s) Of Engagement Activity 2007,2008,2009,2010,2011,2012,2013,2014,2015,2016
 
Description Singapore National Medical Research Council 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Translational and Clinical research flagship programme review panel member

2012 to present .
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
 
Description Sir Jules Thorn Medical Research Trust International Autozygosity Mapping Resource 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Steering Group Chairman, 2009 to present .
Year(s) Of Engagement Activity 2009,2010,2011,2012,2013,2014,2015,2016
 
Description Snap, Crackle & Pop - an update on contrast microbubble research in Edinburgh 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact MNP Seminar, University of Leeds.



Dr Carmel Moran, Reader in Medical Physics, University of Edinburgh.
Year(s) Of Engagement Activity 2011
 
Description The use of light, sound and microbubbles for molecular imaging and therapy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited talk at the Institute of Cancer Research.

Invited talk in London
Year(s) Of Engagement Activity 2011
 
Description The use of optically activated nanoparticles under tension to enhance photoacoustic imaging and high intensity focused ultrasound exposures 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Invited talk at IMSAT.

Invited talk in Dundee
Year(s) Of Engagement Activity 2011
 
Description Tumour Vascular profiling with contrast enhanced high frequency ultrasound (Dublin 2013) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Invited Presentation

March 2013, Dublin, Royal College of Surgeons.
Year(s) Of Engagement Activity 2013
 
Description Tumour vascular profiling with contrast enhanced high frequency ultrasound (London 2011) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact British medical ultrasound pre-clinical imaging workshop, 2011 London

Invited presentation.
Year(s) Of Engagement Activity 2011
 
Description World Oncology Forum 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited member - 2012 to present .
Year(s) Of Engagement Activity 2012
 
Description Youtube video 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact YouTube videos - two different versions of an interview with Steve Evans, and one animation which was put together - have so far achieved 960 views in total. What's more impressive is that the average watch time for these shows that most people are staying with them, rather than clicking away. The Animation is 48 seconds long and the average view is 37 seconds; the Steve Evans interview is 2.13 long and the average view is 1:30.
Year(s) Of Engagement Activity 2018